Tracking Industry’s Lawsuits Against IRA’s Medicare Price Negotiations
Executive Summary
Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Scrip's new chart tracks the developments.
You may also be interested in...
Five Key Takeaways From Merck’s Q2 Earnings Release
Keytruda and Gardasil lead Merck’s growth story, although Lagevrio’s ongoing decline placed a drag on quarterly performance. Lung cancer is driving Keytruda’s momentum outside the US.
Medicare Negotiation Guidance Rebuts Accusations Of Constitutional ‘Due Process’ Violations
The final guidance on the Medicare drug price negotiation program also addresses complaints that the government may violate the uncompensated ‘takings’ clause of the Fifth Amendment of the US Constitution in the way it considers remaining patents and exclusivities for negotiated drugs.
PhRMA Teams With Provider And Patient Groups In Suit Against IRA Filed In Texas District Court
Complaint seeks permanent injunction to require drug pricing program to give stakeholders opportunity to comment on the process and make decisions subject to judicial review.